The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Official Title: A Phase II/III, Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of QL1706 in Combination With Bevacizumab and/or Chemotherapy Versus Sintilimab in Combination With Bevacizumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Study ID: NCT05976568
Brief Summary: The purpose of this study is to assess the efficacy and safety of QL1706 in combination with bevacizumab and/or chemotherapy versus sintilimab in combination with bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Nanjing Tianyinshan Hospital, Nanjing, Jiangsu, China
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Name: Jia Fan
Affiliation: Fudan University
Role: PRINCIPAL_INVESTIGATOR
Name: Shukui Qin
Affiliation: Nanjing Tianyinshan Hospital
Role: PRINCIPAL_INVESTIGATOR